Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
7 i3 c$ ^1 |8 n- n
/ y: B, X; b3 L0 A
. @- F. w! [4 i: @' A$ s* P4 zSub-category:; H7 e. M" x. ~8 [7 g9 h" Z9 o
Molecular Targets
: ^; R! n/ P- o6 f7 X% E8 n5 A
: b' d$ ?6 b: @) v- t$ N8 l: D" a
2 ?% b6 [; d: A$ V9 O. M0 zCategory:
" o- m" u, D2 [; F m* lTumor Biology & G/ m# G+ o$ E! T; A) j
0 F# ?+ P5 p+ ?
+ v4 K. O2 Q$ {* I- V* O) ZMeeting:
' M* v5 \7 c0 w: U0 e2011 ASCO Annual Meeting * G0 r% ~. a& a7 C& }9 x; @
- e- H+ p; D7 f9 P4 h1 h8 w1 o' G! ^
Session Type and Session Title:! R( U' H% J w; }+ w' Q4 G4 _: ~
Poster Discussion Session, Tumor Biology ; N4 |9 k# U z+ r' ^
& ?8 C6 a8 V( @4 c6 u8 k% l+ S- n
- F! ~& b+ y: q8 ?: T) zAbstract No:
9 J4 c& H' R1 I @10517
1 n5 d6 v7 v( h: w8 Q1 M3 C+ n+ U! b$ V' W5 b
$ F' D/ U4 w# I- \Citation:+ x7 W5 L, Z# V: v; D/ M/ C
J Clin Oncol 29: 2011 (suppl; abstr 10517)
+ k$ F) |! Y+ N# E
B7 P; ^7 L/ i. m( w) l5 Y, `
+ g: D6 W. \- V7 Z& PAuthor(s):9 ?4 T; Z. S5 K; |1 [
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China " H3 X7 {3 T7 W! `* v
) J% k" {% M5 q0 L- F8 i
$ u. E# H( s% q+ A( b! N
8 c; E) Q. q! ^! JAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
3 z e- C0 X: k6 P, T1 ]/ L, D, G. w. Q4 V0 o" z7 ~7 g9 I
Abstract Disclosures
/ C6 K- S7 _* s8 p Z* k8 w- u, r6 ~7 B! @- u' P2 Y5 p
Abstract:
7 h5 U! r! A3 D+ J. H/ I) ]2 Q7 K# q5 g8 {7 _! I5 C: x
5 f g1 W! {- j. K6 ~+ y
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
( z0 f& l" b1 _
) T* ~( u& B! B" j6 }
. J( L2 a" p+ E, B) G( w |
6 g( y& _# m- s
显身卡
